Symbols / NXTC Stock $9.25 -3.85% NextCure, Inc.

Healthcare • Biotechnology • United States • NMS
NXTC (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Michael S. Richman MSBA
Exch · Country NMS · United States
Market Cap 33.37M
Enterprise Value -2.41M
Income -55.84M
Sales —
FCF (ttm) -28.80M
Book/sh 9.97
Cash/sh 11.74
Employees 40
Insider 10d —
IPO May 09, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.47
PEG —
P/S —
P/B 0.93
P/C —
EV/EBITDA 0.04
EV/Sales —
Quick Ratio 3.97
Current Ratio 4.14
Debt/Eq 14.75
LT Debt/Eq —
EPS (ttm) -19.65
EPS next Y -6.31
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-05
Earnings (prior) 2026-03-05
ROA -54.96%
ROE -111.23%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 3.61M
Shs Float 2.23M
Insider Own 14.98%
Instit Own 48.40%
Short Float 2.05%
Short Ratio 1.51
Short Interest 72.01K
52W High 15.74
vs 52W High -41.23%
52W Low 4.09
vs 52W Low 126.05%
Beta 1.58
Impl. Vol. —
Rel Volume 0.30
Avg Volume 49.76K
Volume 14.77K
Target (mean) $17.67
Tgt Median $18.00
Tgt Low $15.00
Tgt High $20.00
# Analysts 3
Recom None
Prev Close $9.62
Price $9.25
Change -3.85%
About

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$17.67
Mean price target
2. Current target
$9.25
Latest analyst target
3. DCF / Fair value
$-143.69
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.25
Low
$15.00
High
$20.00
Mean
$17.67

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-11-07 up Ladenburg Thalmann Neutral → Buy $18
2025-07-15 main Piper Sandler Overweight → Overweight $15
2025-07-01 reit HC Wainwright & Co. Buy → Buy $3
2025-03-17 reit HC Wainwright & Co. Buy → Buy $3
2025-03-07 reit HC Wainwright & Co. Buy → Buy $3
2024-11-11 main HC Wainwright & Co. Buy → Buy $4
2024-08-02 reit Needham Buy → Buy $4
2024-06-03 reit HC Wainwright & Co. Buy → Buy $8
2024-05-31 reit HC Wainwright & Co. Buy → Buy $8
2024-05-03 reit HC Wainwright & Co. Buy → Buy $8
2024-05-03 reit Needham Buy → Buy $4
2024-03-22 main HC Wainwright & Co. Buy → Buy $8
2024-03-20 main Needham Buy → Buy $4
2023-12-14 main Needham Buy → Buy $4
2023-08-08 init HC Wainwright & Co. — → Buy $7
2023-08-04 reit Needham Buy → Buy $6
2023-05-05 reit Needham — → Buy $6
2023-03-03 reit Needham — → Buy $6
2022-11-04 down Ladenburg Thalmann Buy → Neutral —
2022-11-04 main Needham — → Buy $6
News
RSS: Latest NXTC news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
57.62
+0.72%
57.21
-15.42%
67.64
-10.90%
75.91
Research And Development
44.92
+8.28%
41.49
-13.44%
47.93
-11.56%
54.20
Selling General And Administration
12.69
-19.25%
15.72
-20.24%
19.71
-9.23%
21.71
General And Administrative Expense
12.69
-19.25%
15.72
-20.24%
19.71
-9.23%
21.71
Other Gand A
12.69
-19.25%
15.72
-20.24%
19.71
-9.23%
21.71
Total Expenses
57.62
+0.72%
57.21
-15.42%
67.64
-10.90%
75.91
Operating Income
-57.62
-0.72%
-57.21
+15.42%
-67.64
+10.90%
-75.91
Total Operating Income As Reported
-57.62
+3.57%
-59.75
+11.66%
-67.64
+10.90%
-75.91
EBITDA
-55.43
-2.01%
-54.34
+15.03%
-63.95
+10.91%
-71.78
Normalized EBITDA
-55.43
-7.01%
-51.80
+19.00%
-63.95
+10.91%
-71.78
Reconciled Depreciation
2.19
-23.73%
2.87
-22.23%
3.68
-10.67%
4.12
EBIT
-57.62
-0.72%
-57.21
+15.42%
-67.64
+10.90%
-75.91
Total Unusual Items
0.00
+100.00%
-2.54
0.00
—
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-2.54
0.00
—
Special Income Charges
0.00
+100.00%
-2.54
0.00
—
Restructuring And Mergern Acquisition
0.00
-100.00%
2.54
0.00
—
Net Income
-55.84
-0.34%
-55.65
+11.27%
-62.72
+16.07%
-74.73
Pretax Income
-55.84
-0.34%
-55.65
+11.27%
-62.72
+16.07%
-74.73
Other Income Expense
1.77
+14.18%
1.55
-68.42%
4.91
+317.86%
1.18
Other Non Operating Income Expenses
1.77
-56.72%
4.09
-16.69%
4.91
+317.86%
1.18
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-55.84
-0.34%
-55.65
+11.27%
-62.72
+16.07%
-74.73
Net Income From Continuing Operation Net Minority Interest
-55.84
-0.34%
-55.65
+11.27%
-62.72
+16.07%
-74.73
Net Income From Continuing And Discontinued Operation
-55.84
-0.34%
-55.65
+11.27%
-62.72
+16.07%
-74.73
Net Income Continuous Operations
-55.84
-0.34%
-55.65
+11.27%
-62.72
+16.07%
-74.73
Normalized Income
-55.84
-5.14%
-53.11
+15.32%
-62.72
+16.07%
-74.73
Net Income Common Stockholders
-55.84
-0.34%
-55.65
+11.27%
-62.72
+16.07%
-74.73
Diluted EPS
-19.65
+17.71%
-23.88
+11.56%
-27.00
+16.36%
-32.28
Basic EPS
-19.65
+17.71%
-23.88
+11.56%
-27.00
+16.36%
-32.28
Basic Average Shares
2.84
+21.97%
2.33
+0.46%
2.32
+0.33%
2.31
Diluted Average Shares
2.84
+21.97%
2.33
+0.46%
2.32
+0.33%
2.31
Diluted NI Availto Com Stockholders
-55.84
-0.34%
-55.65
+11.27%
-62.72
+16.07%
-74.73
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
50.18
-37.94%
80.86
-36.85%
128.04
-30.47%
184.16
Current Assets
43.75
-39.08%
71.81
-36.30%
112.72
-31.26%
163.98
Cash Cash Equivalents And Short Term Investments
41.82
-39.06%
68.62
-36.64%
108.30
-32.28%
159.91
Cash And Cash Equivalents
25.98
-6.29%
27.73
+111.95%
13.08
-50.87%
26.63
Other Short Term Investments
15.84
-61.28%
40.89
-57.05%
95.22
-28.56%
133.28
Prepaid Assets
—
—
—
—
Restricted Cash
—
—
—
—
Other Current Assets
1.93
-39.45%
3.19
-28.02%
4.43
+8.69%
4.07
Total Non Current Assets
6.44
-28.91%
9.05
-40.88%
15.31
-24.11%
20.18
Net PPE
5.89
-32.46%
8.72
-35.07%
13.43
-20.59%
16.91
Gross PPE
31.17
-2.03%
31.82
-5.48%
33.66
+0.35%
33.54
Accumulated Depreciation
-25.28
-9.46%
-23.09
-14.17%
-20.23
-21.64%
-16.63
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.09
+0.00%
1.09
+0.00%
1.09
+0.00%
1.09
Construction In Progress
—
0.00
-100.00%
0.23
-73.62%
0.85
Other Properties
20.77
-3.02%
21.41
-7.03%
23.03
+3.47%
22.26
Leases
9.31
+0.00%
9.31
+0.00%
9.31
-0.29%
9.34
Other Non Current Assets
0.55
+64.46%
0.33
-82.36%
1.88
-42.36%
3.27
Total Liabilities Net Minority Interest
15.24
-0.96%
15.39
+13.01%
13.62
-18.12%
16.63
Current Liabilities
10.57
+10.36%
9.57
+39.10%
6.88
-24.59%
9.13
Payables And Accrued Expenses
9.43
+8.92%
8.65
+41.54%
6.11
-28.10%
8.50
Payables
2.01
-62.43%
5.35
+129.74%
2.33
-45.43%
4.27
Accounts Payable
2.01
-62.43%
5.35
+129.74%
2.33
-45.43%
4.27
Current Accrued Expenses
7.42
+124.63%
3.30
-12.76%
3.78
-10.63%
4.23
Current Debt And Capital Lease Obligation
1.00
+26.26%
0.80
+21.34%
0.66
+26.64%
0.52
Current Capital Lease Obligation
1.00
+26.26%
0.80
+21.34%
0.66
+26.64%
0.52
Current Deferred Liabilities
—
—
—
—
Other Current Liabilities
0.14
+8.87%
0.12
+9.73%
0.11
+7.62%
0.10
Total Non Current Liabilities Net Minority Interest
4.67
-19.61%
5.81
-13.66%
6.73
-10.26%
7.50
Long Term Debt And Capital Lease Obligation
4.15
-19.50%
5.15
-13.38%
5.95
-9.93%
6.61
Long Term Capital Lease Obligation
4.15
-19.50%
5.15
-13.38%
5.95
-9.93%
6.61
Non Current Deferred Liabilities
—
—
—
—
Other Non Current Liabilities
0.53
-20.42%
0.66
-15.80%
0.79
-12.68%
0.90
Stockholders Equity
34.94
-46.63%
65.47
-42.78%
114.42
-31.70%
167.53
Common Stock Equity
34.94
-46.63%
65.47
-42.78%
114.42
-31.70%
167.53
Capital Stock
0.00
+100.00%
0.00
-92.86%
0.03
+0.00%
0.03
Common Stock
0.00
+100.00%
0.00
-92.86%
0.03
+0.00%
0.03
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
3.51
+50.21%
2.33
+0.37%
2.33
+0.46%
2.31
Ordinary Shares Number
3.51
+50.21%
2.33
+0.37%
2.33
+0.46%
2.31
Additional Paid In Capital
470.90
+5.68%
445.60
+1.48%
439.10
+1.94%
430.75
Retained Earnings
-435.98
-14.69%
-380.14
-17.15%
-324.48
-23.96%
-261.76
Gains Losses Not Affecting Retained Earnings
0.02
+425.00%
0.00
+101.80%
-0.22
+85.14%
-1.49
Other Equity Adjustments
0.02
+425.00%
0.00
+101.80%
-0.22
+85.14%
-1.49
Total Equity Gross Minority Interest
34.94
-46.63%
65.47
-42.78%
114.42
-31.70%
167.53
Total Capitalization
34.94
-46.63%
65.47
-42.78%
114.42
-31.70%
167.53
Working Capital
33.18
-46.68%
62.23
-41.20%
105.84
-31.65%
154.86
Invested Capital
34.94
-46.63%
65.47
-42.78%
114.42
-31.70%
167.53
Total Debt
5.15
-13.38%
5.95
-9.93%
6.61
-7.27%
7.12
Capital Lease Obligations
5.15
-13.38%
5.95
-9.93%
6.61
-7.27%
7.12
Net Tangible Assets
34.94
-46.63%
65.47
-42.78%
114.42
-31.70%
167.53
Tangible Book Value
34.94
-46.63%
65.47
-42.78%
114.42
-31.70%
167.53
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-49.61
-21.59%
-40.80
+22.97%
-52.97
+1.69%
-53.89
Cash Flow From Continuing Operating Activities
-49.61
-21.59%
-40.80
+22.97%
-52.97
+1.69%
-53.89
Net Income From Continuing Operations
-55.84
-0.34%
-55.65
+11.27%
-62.72
+16.07%
-74.73
Depreciation Amortization Depletion
2.19
-23.73%
2.87
-22.23%
3.68
-10.67%
4.12
Depreciation And Amortization
2.19
-23.73%
2.87
-22.23%
3.68
-10.67%
4.12
Other Non Cash Items
0.59
+4.63%
0.56
-2.09%
0.57
+60.96%
0.36
Stock Based Compensation
2.99
-52.87%
6.33
-22.63%
8.19
-13.88%
9.51
Asset Impairment Charge
0.00
-100.00%
1.79
0.00
—
Operating Gains Losses
—
—
—
0.09
Gain Loss On Sale Of PPE
—
—
0.00
-100.00%
0.09
Change In Working Capital
0.95
-78.95%
4.53
+333.61%
-1.94
-152.08%
3.73
Change In Prepaid Assets
1.10
-60.09%
2.76
+157.08%
1.07
-47.30%
2.04
Change In Payables And Accrued Expense
0.99
-63.14%
2.69
+219.92%
-2.24
-233.02%
1.69
Change In Accrued Expense
4.33
+1405.42%
-0.33
-9.21%
-0.30
+52.57%
-0.64
Change In Payable
-3.34
-210.55%
3.02
+255.82%
-1.94
-183.33%
2.33
Change In Account Payable
-3.34
-210.55%
3.02
+255.82%
-1.94
-183.33%
2.33
Change In Other Working Capital
—
—
—
—
Change In Other Current Liabilities
-1.14
-23.91%
-0.92
-19.48%
-0.77
0.00
Investing Cash Flow
25.56
-53.79%
55.31
+40.83%
39.27
-42.23%
67.98
Cash Flow From Continuing Investing Activities
25.56
-53.79%
55.31
+40.83%
39.27
-42.23%
67.98
Net PPE Purchase And Sale
0.00
+100.00%
-0.47
+42.20%
-0.82
+61.25%
-2.12
Purchase Of PPE
0.00
+100.00%
-0.47
+42.20%
-0.82
+61.25%
-2.12
Capital Expenditure
—
-0.47
+42.20%
-0.82
+61.25%
-2.12
Net Investment Purchase And Sale
25.56
-54.18%
55.78
+39.13%
40.09
-42.80%
70.09
Purchase Of Investment
-26.70
+44.88%
-48.45
+34.09%
-73.50
-112.17%
-34.64
Sale Of Investment
52.26
-49.86%
104.23
-8.25%
113.60
+8.46%
104.74
Financing Cash Flow
22.31
+15394.44%
0.14
-6.49%
0.15
-23.00%
0.20
Cash Flow From Continuing Financing Activities
22.31
+15394.44%
0.14
-6.49%
0.15
-23.00%
0.20
Net Issuance Payments Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
22.28
+57017.95%
0.04
+680.00%
0.01
—
Proceeds From Stock Option Exercised
0.04
-65.71%
0.10
-29.53%
0.15
-25.50%
0.20
Changes In Cash
-1.75
-111.92%
14.64
+208.10%
-13.55
-194.79%
14.29
Beginning Cash Position
27.73
+111.95%
13.08
-50.87%
26.63
+115.85%
12.34
End Cash Position
25.98
-6.29%
27.73
+111.95%
13.08
-50.87%
26.63
Free Cash Flow
-49.61
-20.19%
-41.28
+23.26%
-53.79
+3.94%
-56.00
Interest Paid Supplemental Data
0.06
-13.89%
0.07
-11.11%
0.08
-10.00%
0.09
Income Tax Paid Supplemental Data
—
—
—
—
Amortization Of Securities
-0.48
+60.89%
-1.23
-62.70%
-0.76
-124.81%
3.05
Common Stock Issuance
22.28
+57017.95%
0.04
+680.00%
0.01
—
Issuance Of Capital Stock
22.28
+57017.95%
0.04
+680.00%
0.01
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category